Evaluation of Polmacoxib 2 mg for the Management of Hip and Knee Osteoarthritis: A Prospective, Single-Arm, Multicenter, Open-Label Study
Polmacoxib 2 mg demonstrated early onset of symptom relief, significant improvements in clinical symptoms, and an acceptable safety and tolerability profile over a six-week treatment period, suggesting that polmacoxib is a well-tolerated treatment option for osteoarthritis patients necessitating effective and rapid symptom control with minimal systemic side effects.
Authors
- Pravin Waghmare
- Sujay Patil
- Rakesh Verma (ORCID: https://orcid.org/0000-0003-2078-4415)
- Milind Bhole (ORCID: https://orcid.org/0000-0003-2441-5297)
- Sanjeev Kumar Kare
- Swapnil Deshpande (ORCID: https://orcid.org/0000-0001-9885-7958)
- Urvi K Mistry
- Rajiv Gupta (ORCID: https://orcid.org/0000-0002-5882-960X)
- Amritaksha Kar (ORCID: https://orcid.org/0000-0002-7804-1641)
Institutions
- Memorial Hospital of South Bend (US)
- Abbott (United Kingdom) (GB)
- Midas Multispeciality Hospital (IN)
- Jawaharlal Nehru Medical College (IN)
- Abbott (India) (IN)
- Sri Gokulam Hospital (IN)
- Bhagwan Mahaveer Cancer Hospital and Research Centre (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-18
- DOI
- https://doi.org/10.7759/cureus.94838
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00